For more than two decades, Medicare has been legally prohibited from covering medications prescribed for weight loss. The Medicare Modernization Act of 2003 explicitly excluded "agents when used for anorexia, weight loss, or weight gain" from Part D coverage, a policy written at a time when anti-obesity drugs were largely ineffective and carried serious safety concerns. Starting in mid-2026, millions of Medicare beneficiaries will gain access to tirzepatide and other GLP-1 medications for weight management through a combination of federal demonstration programs, manufacturer pricing agreements, and a new voluntary coverage model called BALANCE. The shift is neither simple nor universal. Eligibility will depend on clinical criteria, plan participation, and a phased rollout that will take years to fully mature.
Why Medicare's Weight-Loss Drug Ban Lasted This Long
When Congress wrote Part D into law, the anti-obesity drugs available at the time, primarily phentermine-based combinations and sibutramine, had modest efficacy and significant cardiovascular risks. Sibutramine was eventually pulled from the market entirely. The exclusion was designed as a patient-safety guardrail, modeled on a similar provision in Medicaid.
The problem is that science moved while the statute stayed put. Beginning with liraglutide in 2014 and accelerating sharply with the approval of semaglutide and tirzepatide, the GLP-1 drug class has demonstrated weight-loss results of 15 to 22 percent of body weight, along with evidence of cardiovascular protection, blood pressure reduction, and improved glycemic control. The Congressional Budget Office estimated that more than two-thirds of Medicare beneficiaries are either overweight or obese, with approximately 12.5 million who would become newly eligible for anti-obesity medications if coverage were expanded.
Medicare’s current policy explicitly excludes coverage for GLP-1 medications prescribed solely for weight loss, a restriction rooted in the Medicare Modernization Act of 2003. This exclusion means that, regardless of a patient’s clinical need or physician recommendation, Medicare Part D will not pay for GLP-1 drugs like tirzepatide, semaglutide, or liraglutide when used only for weight management. However, Medicare does cover these medications when they are prescribed for other FDA-approved indications, such as type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea.
Coverage depends on the specific Medicare Part D plan’s formulary, which lists approved drugs and may impose additional requirements like prior authorization, step therapy, or quantity limits. For example, a plan may cover Ozempic for diabetes but not for weight loss, and may require your physician to submit documentation to justify the prescription. Beneficiaries should consult their plan’s drug list to confirm coverage for their specific indication. It’s essential to distinguish between current policy, where weight-loss-only use is excluded, and future possibilities, as pilot programs and demonstration models may expand access, but these are not yet universally available and remain subject to ongoing policy development.
Common GLP-1 Medications and Their Typical Medicare Coverage Status
GLP-1 medications are a class of drugs increasingly prescribed for managing type 2 diabetes, obesity, and related conditions. The most frequently prescribed GLP-1 medications include semaglutide, tirzepatide, dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda). Under Medicare, coverage for these medications is closely tied to their FDA-approved uses. Drugs such as Ozempic, Rybelsus, Mounjaro, Trulicity, and Victoza are typically covered when prescribed for type 2 diabetes or for reducing cardiovascular risk in patients with diabetes. Wegovy and Zepbound, which are approved for chronic weight management, are generally not covered for weight loss alone. However, they may be covered for other approved uses, such as reducing cardiovascular risk or treating obstructive sleep apnea (Zepbound). Coverage specifics vary by Medicare Part D plan, so beneficiaries should always verify details with their plan administrator.
The November 2025 Deal: What the Government Negotiated
On November 6, 2025, the two companies that manufacture virtually all GLP-1 medications on the market announced that they will lower prices and expand access for Medicare, Medicaid, and self-pay consumers. The deal introduced two parallel tracks.
The first was a set of negotiated prices. For Medicare, the agreed-upon cost to the program would be $245 per month for diabetes-indicated drugs and $350 per month (decreasing over two years) for weight-loss-indicated medications. Eligible Medicare beneficiaries would pay a flat $50 copay per month. For Eli Lilly specifically, the agreement covers Zepbound and, pending FDA approval, orforglipron, an investigational once-daily oral GLP-1 pill that could receive regulatory clearance as early as mid-2026.
The second track was the eligibility criteria. Coverage would not be available to all Medicare beneficiaries who want to lose weight. Instead, access would be limited to patients at high metabolic or cardiovascular risk, with a phased rollout tied to specific clinical thresholds.
How Eligibility Is Phased In: The Three-Stage Rollout
The expansion of Medicare coverage for GLP-1 medications will follow a tiered structure that prioritizes beneficiaries with the highest immediate health risks. The timeline and criteria break down as follows:
- Phase 1 (mid-2026): Beneficiaries with a BMI greater than 27 who also have a diagnosis of prediabetes, established cardiovascular disease, or a history of stroke. This is the narrowest tier, focused on patients where clinical evidence most clearly supports that GLP-1 treatment can reduce the risk of serious adverse events beyond weight loss alone.
- Phase 2 (late 2026 to early 2027): Those with a BMI greater than 30 who have uncontrolled hypertension despite treatment, advanced kidney disease, or heart failure. This phase captures the broader population of obese beneficiaries whose weight is compounding existing chronic conditions, even if they do not yet meet the cardiovascular thresholds of Phase 1.
- Phase 3 (2028 and beyond): Potential expansion to beneficiaries with a BMI greater than 35, with criteria refined based on outcomes data from the first two phases. CMS has indicated this stage will be informed by real-world results from the demonstration, including adherence rates, clinical outcomes, and program costs.
- Important exclusion: Medicare beneficiaries who want a GLP-1 medication for weight loss alone will not be eligible under any current phase. The program is designed around treating obesity as a disease driver, not as a cosmetic concern.
- Documentation requirements: Qualifying diagnoses must be supported by medical records. BMI must be documented by a healthcare provider, and comorbidities like prediabetes, cardiovascular disease, or chronic kidney disease will likely require ICD-10 coding and supporting lab work.
Beneficiaries seeking to determine if medications like tirzepatide are covered by their Medicare plan should begin by consulting their plan’s Drug List (formulary), which details all covered medications and any associated requirements such as prior authorization, step therapy, or quantity limits. This list can typically be found on the plan’s website or obtained by contacting the plan directly. It’s important to look up the specific drug name and dosage, as coverage can vary based on indication and formulation. If prior authorization is required, the beneficiary’s healthcare provider must submit documentation confirming the diagnosis and eligibility. Beneficiaries can also call the customer service number on their Medicare card for personalized assistance, ensuring they have the most up-to-date information about their coverage options.
The July 2026 Bridge Demonstration and the BALANCE Model
The operational mechanics of the coverage expansion involve two distinct but interconnected federal programs. A short-term bridge demonstration launching in July 2026 and a longer-term voluntary model called BALANCE beginning in January 2027.
The bridge demonstration is designed to get medications into beneficiaries' hands as quickly as possible. Unlike standard Part D coverage, this demonstration will operate entirely outside the Part D benefit structure. CMS will administer it directly, which means Part D plan sponsors will not carry financial risk for GLP-1 drugs dispensed under the program. Beneficiaries enrolled in any Part D plan who meet the negotiated eligibility criteria will be able to access covered medications at a $50 monthly copay. CMS has stated it will release additional implementation details in early 2026, with the program expected to go live in July.
The BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) Model, announced by CMS on December 23, 2025, is the longer-term framework. Under BALANCE, CMS negotiates drug pricing and coverage terms directly with participating manufacturers on behalf of state Medicaid agencies and Medicare Part D plan sponsors. Participation is voluntary for manufacturers, states, and plans, which means coverage under BALANCE is not guaranteed for every beneficiary. It depends on which entities opt in. All beneficiaries receiving GLP-1 medications for weight management through the model must also receive access to a manufacturer-funded lifestyle support program at no additional cost. These programs are designed to help patients incorporate dietary changes and physical activity consistent with FDA labeling, which recommends GLP-1s as an adjunct to lifestyle modification rather than a standalone treatment. Testing of the BALANCE model will continue through December 2031.
What Tirzepatide Specifically Brings to the Table
Tirzepatide holds a unique position in this policy shift due to its dual mechanism and its expanding list of FDA-approved indications. As a GIP/GLP-1 receptor agonist, it activates both GIP and GLP-1 receptors, producing greater appetite suppression and metabolic improvement than single-receptor drugs. Tirzepatide currently has three relevant FDA approvals:
- Mounjaro (tirzepatide) for type 2 diabetes. Approved in 2022, Mounjaro is already covered by more than 90 percent of Part D plans when prescribed for blood sugar control. Beneficiaries with diabetes can access it through standard Part D pathways, and the new demonstration programs do not alter this coverage.
- Zepbound (tirzepatide) for chronic weight management. Zepbound is indicated for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. This is the indication that triggers the new Medicare coverage programs.
- Zepbound (tirzepatide) for obstructive sleep apnea. Approved in December 2024, this makes Zepbound the first medication ever approved by the FDA for moderate-to-severe OSA in adults with obesity. In the SURMOUNT-OSA trials, tirzepatide reduced breathing disruptions by 25 to 29 events per hour and produced 18 to 20 percent body weight loss.
A beneficiary who has both obesity and sleep apnea, for instance, may not need to wait for the new demonstration program at all. A beneficiary with diabetes and obesity may be able to access tirzepatide now through the diabetes indication. Understanding the full map of approvals helps identify the fastest route to coverage.
The Cost Picture: What $50 a Month Actually Means
The $50 monthly copay under the demonstration program represents an enormous reduction from the current self-pay cost of tirzepatide, which runs between $1,000 and $1,400 per month without insurance.
- The $50 copay applies only to beneficiaries who qualify for and enroll in the demonstration program or a participating BALANCE plan. If your Part D plan does not participate, or if you do not meet the eligibility criteria, the negotiated price does not apply to you.
- The Part D out-of-pocket cap provides a separate safety net. Once your spending on covered Part D drugs hits that threshold, you enter catastrophic coverage and pay nothing for the rest of the year. If tirzepatide is covered under your plan for a non-weight-loss indication (diabetes, sleep apnea), your costs are already capped.
- Oral options may shift the math. Orforglipron, Eli Lilly's once-daily oral GLP-1 pill, received FDA priority review and could be approved as early as mid-2026. Upon approval, it would also be available through the Medicare demonstration at $50 per month.
- Manufacturer assistance programs still exist. Even before the demonstration launches, some beneficiaries may qualify for manufacturer savings cards or patient assistance programs that reduce out-of-pocket costs on currently covered indications.
- Prior authorization will likely be required. CMS has indicated that beneficiaries will be subject to utilization management criteria, including prior authorization. This means your physician will need to submit documentation of your qualifying diagnosis, BMI, and comorbidities before coverage is approved.
- Platforms like Harbor can help bridge the gap. For beneficiaries who want to start treatment before the demonstration goes live, or who do not meet the demonstration's eligibility criteria, physician-guided weight management platforms provide clinical oversight, prescription access, and ongoing monitoring.
What You Should Do Now to Prepare
Schedule an appointment specifically to discuss GLP-1 therapy. Ask your physician to document your BMI, any qualifying comorbidities, and relevant lab work. ICD-10 coding on your medical record will matter when prior authorization is required. The more complete your clinical documentation is before the program launches, the faster you can move when enrollment opens.
Review your Part D plan carefully. Not all plans will participate in BALANCE, and the bridge demonstration operates outside of standard Part D. Call the number on your Medicare card and ask directly whether your plan intends to participate in the CMS GLP-1 payment demonstration launching in July 2026. If the answer is no, note that the next Medicare Open Enrollment period runs from October 15 to December 7, 2026, for coverage beginning January 2027 when BALANCE fully integrates into Part D.
If you have type 2 diabetes, tirzepatide may already be available to you through your current Part D plan as Mounjaro. If you have moderate-to-severe obstructive sleep apnea and obesity, Zepbound's sleep apnea indication may provide a covered pathway today. These existing indications do not require you to wait for the new demonstration. Also, monitor CMS announcements. The agency has stated that additional details on the bridge demonstration will be released in early 2026, including specific enrollment procedures, qualifying documentation requirements, and a list of participating pharmacies.
Consider whether starting treatment now makes sense. For some beneficiaries, waiting until July means delaying treatment for conditions that are actively progressing. Obesity-driven hypertension, worsening sleep apnea, or advancing prediabetes do not pause for policy timelines. If your clinical situation warrants earlier action, discuss with your provider whether accessing tirzepatide through a current covered indication or through a physician-guided platform is appropriate while the broader coverage programs take shape. You can check whether you may be a candidate by starting with a quick eligibility assessment.
Alternative Weight Loss Treatments Covered by Medicare
Medicare is expanding coverage for GLP-1 medications for weight management, but it may also cover other options, including behavioral, nutritional, and surgical interventions for obesity and related conditions.
1. Obesity Counseling (Intensive Behavioral Therapy) - Medicare Part B covers intensive behavioral therapy for beneficiaries with a BMI of 30 or higher. This includes regular counseling with a primary care provider at no cost to eligible individuals.
2. Medical Nutrition Therapy (MNT) - Medicare Part B covers medical nutrition therapy for those with diabetes or kidney disease, provided by a registered dietitian after a doctor’s referral.
3. Bariatric Surgery - Medicare covers certain bariatric surgeries for beneficiaries with a BMI of 35 or more, a related health condition, and failed attempts at supervised weight loss, if medical criteria are met.
4. Lifestyle Support Programs - Many Medicare Advantage plans offer structured programs like weight management classes and exercise programs to support healthy habits, often alongside other treatments.
Consult your healthcare provider to determine which alternatives are appropriate and likely to be covered by your Medicare plan, as coverage depends on your plan, health, and medical documentation.
Frequently Asked Questions about Medicare GLP-1 Coverage
Medicare’s evolving approach to GLP-1 medications has raised many questions for beneficiaries. Below are answers to some of the most common concerns about eligibility, off-label prescribing, and cost assistance.
Certainly! Here is the section rewritten in question and answer (Q&A) form, focusing on eligibility, off-label use, and assistance programs for Medicare GLP-1 coverage:
Who will be eligible for Medicare coverage of GLP-1 drugs for weight management?
Eligibility for Medicare coverage of GLP-1 medications will be phased in beginning mid-2026. Initially, coverage will be available to beneficiaries who meet specific clinical criteria, such as having a BMI above a certain threshold and at least one qualifying condition like prediabetes, cardiovascular disease, or obstructive sleep apnea. Not all Medicare Part D plans or drug manufacturers will participate in the new voluntary BALANCE model, so coverage may also depend on your plan’s involvement. In all cases, your healthcare provider will need to document your BMI, relevant diagnoses, and supporting lab work to meet prior authorization requirements.
Does Medicare cover GLP-1 drugs prescribed for off-label uses?
No, Medicare does not cover GLP-1 medications for off-label uses. Coverage is strictly limited to FDA-approved indications or select medically accepted uses. If a GLP-1 drug is prescribed for a purpose not recognized by the FDA—such as weight loss alone without qualifying comorbidities—Medicare will not cover it, even if your doctor recommends it.
What if my GLP-1 medication is not on my plan’s formulary?
If your prescribed GLP-1 medication isn’t listed on your plan’s drug formulary, you have options. You can ask your provider about alternative medications that are covered by your plan, or your doctor can submit a request for a formulary exception with medical justification. Approval for such exceptions is not guaranteed and is decided on a case-by-case basis. As new demonstration programs and the BALANCE model roll out, plan formularies may change, so it’s important to review your coverage options regularly.
Are there programs to help with the cost of GLP-1 medications?
Yes, several assistance programs are available. Many beneficiaries qualify for Extra Help (Low-Income Subsidy) or state pharmaceutical assistance programs, which can lower out-of-pocket expenses. Some drug manufacturers also offer savings cards or patient assistance programs that may be available even before the Medicare demonstration launches. Once the new demonstration or BALANCE program begins, those who qualify will have their monthly out-of-pocket cost for GLP-1 medications capped at $50.
Future Prospects for Medicare Coverage
Medicare’s approach to weight-loss drug coverage is on the brink of significant transformation, driven by evolving policy trends and increasing legislative attention. Historically, Medicare Part D has excluded coverage for medications prescribed solely for weight loss, a policy rooted in past safety concerns and limited drug efficacy. However, the advent of highly effective GLP-1 medications, such as tirzepatide and semaglutide, has prompted a reevaluation of these restrictions. Federal initiatives like the upcoming BALANCE demonstration model, set to launch in 2026, signal a willingness to pilot expanded access for select beneficiaries meeting specific clinical criteria. This shift is also fueled by mounting advocacy from medical organizations and patient groups urging Congress to remove statutory exclusions. If demonstration programs prove successful in improving health outcomes and controlling costs, there is growing momentum for permanent legislative reform. The next few years will be pivotal in determining whether these pilot programs lead to lasting change in Medicare’s coverage of weight-loss drugs.
The future of Medicare coverage for weight-loss drugs is being shaped by a combination of legislative advocacy and evolving policy priorities. Medical organizations, patient advocacy groups, and some members of Congress are now pushing to revisit statutory exclusions, arguing that obesity is a chronic disease deserving of pharmaceutical intervention.
Uncertainty and Conditional Nature of Future Coverage
Despite these promising developments, the path to expanded Medicare coverage for weight-loss drugs remains uncertain and highly conditional. The new demonstration programs, including the bridge demonstration and the BALANCE model, are voluntary and experimental. Not all Medicare Part D plans or drug manufacturers are required to participate, and eligibility will be limited to beneficiaries who meet specific clinical criteria. The Centers for Medicare & Medicaid Services (CMS) has not finalized all details regarding enrollment, qualifying documentation, or plan participation. This means that, at least initially, access to GLP-1 medications for weight management will vary widely based on plan choices, geographic location, and manufacturer involvement. Current coverage rules remain in effect until these pilots are fully implemented.
What Could Accelerate or Delay Broader Coverage
The timeline for expanded Medicare coverage of weight-loss drugs is phased and subject to change. However, these dates are tentative and depend on CMS guidance, manufacturer agreements, and plan participation. Legislative action to permanently remove the statutory exclusion could accelerate broader coverage, especially if advocacy efforts and demonstration outcomes are favorable. On the other hand, delays in regulatory guidance, lack of participation from key stakeholders, or negative results from the pilots could slow or halt progress.
It is important to distinguish between the temporary nature of the current demonstration programs and the possibility of long-term, nationwide reform. The bridge and BALANCE models are time-limited, voluntary experiments designed to test the feasibility and impact of expanding access to weight-loss drugs for select Medicare beneficiaries. These programs do not amend the underlying statute that excludes weight-loss medications from Medicare Part D; instead, they operate as exceptions under CMS authority. For all Medicare beneficiaries to gain routine access to weight-loss drugs, Congress would need to pass legislation permanently removing the exclusion. Until then, access will remain limited to those who qualify for and enroll in these demonstration models, and the future of coverage will depend on both the results of these pilots and the political will to enact broader change.
The expansion of Medicare coverage for GLP-1 medications represents the federal government's most significant acknowledgment that obesity is a chronic disease requiring pharmaceutical intervention. Whether these programs become permanent depends on outcomes. CMS is explicitly treating this as a test. Advocacy organizations and professional medical societies are pushing for permanent statutory change that would eliminate the Part D weight-loss drug exclusion entirely. For now, the door is opening. The most important thing you can do is make sure you are ready to walk through it.